Login to Your Account

Maxim's Electronic Ceplene Application Is Europe's First

By Nuala Moran

Wednesday, November 12, 2003
LONDON - Maxim Pharmaceuticals Inc. became the first to make an all-electronic submission in Europe last week, when it filed for Ceplene in combination with interleukin-2 for the treatment of advanced malignant melanoma. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription